This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Branded by AVITA Medical and co-developed with Regenity Biosciences, Cohealyx may reduce treatment timelines, and improve patient outcomes in the treatment of full-thickness wounds. The Company expects to launch full commercialization efforts in the beginning of the second quarter of 2025 in the U.S.
“The future of dermatology depends on innovative treatments like VTAMA, and Organon’s acquisition of Dermavant allows us to further expand our existing portfolio of established brands and biosimilar dermatology treatments,” says Kevin Ali, Chief Executive Officer of Organon, in a news release.
Combined company’s flagship brands to include daxibotulinumtoxinA (Daxxify), the RHA filler Collection, SkinPen, PanOxyl, Blue Lizard, and StriVectin. The purchase price represents a premium of 89% over Revance’s closing market price on August 9, 2024, and a 111% premium to Revance’s 60-day volume-weighted average price.
Alexis (Lexi) Stern is Merz Aesthetics’ new Chief Marketing Officer. Stern will join the global leadership team and will be responsible for leading the portfolio and brand strategies. Stern will report directly to Bob Rhatigan, Chief Executive Officer, Merz Aesthetics. Most recently, Ms. Before her role at Coty, Inc.,
Book4Time grew its global footprint, in part, through relationships with global hotel and resort brands; integrations with more than 60 technology providers, including property management systems (PMS) and point-of-sale systems (POS); and its highly efficient remote implementation, training and support capabilities.
Shiseido to Acquire Dr. Dennis Gross Skincare Shiseido Americas Corporation is set to acquire the Dr. Dennis Gross Skincare brand. With the addition of Dr. Dennis Gross Skincare, Shiseido seeks to accelerate and strengthen its core prestige skincare business which includes brands SHISEIDO and Clé de Peau Beauté.
Travelers don’t just want to choose their own adventure – they want to maximize every moment of their time away,” said Chris Nassetta, president and chief executive officer, Hilton. These findings highlight new opportunities for us to innovate across our global portfolio and further enhance guests’ stays.
and Europe of four unique dermal fillers in late-stage development with anticipated regulatory clearances in the second half of 2024 and commercialization under the brand name Estyme (pronounced “esteem”) fillers in 2025. Evolus, Inc. This marks the second agreement Evolus has made with Symatese this year.
and Europe of four unique dermal fillers in late-stage development with anticipated regulatory clearances in the second half of 2024 and commercialization under the brand name Estyme (pronounced “esteem”) fillers in 2025. Evolus, Inc. This marks the second agreement Evolus has made with Symatese this year.
It’s pure commonsense ,” Nathan Jones, chief executive officer of Xlear said in a statement. We are very confident in these results that show Carragelose inactivates SARS-CoV-2, independent of the mutations we tested ,” said Dr. Eva Prieschl-Grassauer, Chief Scientific Officer at Marinomed.
The EU Medical Device Regulation (MDR) certification gave its nod to four injectable hyaluronic acid (HA) gel fillers from Evolus under the brand name Estyme, The CE Mark certification, through the new MDR process, represents more stringent requirements, designed to ensure the safety, efficacy, and quality of medical devices sold in Europe.
This milestone represents an exciting new chapter in our long-term strategy to expand our portfolio and transition from a single-product company to a multi-product innovator, strengthening our leadership in performance beauty, says David Moatazedi, President and Chief Executive Officer of Evolus, in a news release.
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content